Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT04415983
Recruiting Phase 3

Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children

NCT04415983 · tracked via the Priya Life Science Egypt tracker
Sponsor
Tanta University
Phase
Phase 3
Started
2020-06-01
Last updated
2020-06-04

Condition(s) studied

Helicobacter Pylori Infection

Investigational drug(s) / intervention(s)

Nitazoxanide →Clarithromycin →Metronidazole →Proton pump inhibitor

Nitazoxanide: Nitazoxanide twice daily

Clarithromycin: Klacid twice daily

Metronidazole: Metronidazole twice daily

Proton pump inhibitor: Omeprazoe twice daily

Study summary

Study of Nitazoxanide (NTZ) based therapeutic regimens for Helicobacter pylori in children

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: \- Positive helicobacter infection. Exclusion Criteria: * Previous treatment for H. Pylori.

Primary outcome measure(s)

  • Number of patients with cured helicobacter infection — 6 months
    Total number of patients with eradicated helicobacter infection

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Tanta Egypt Recruiting

More Tanta University trials in Egypt

Carotid Ultrasound for Post-Spinal Anesthesia Hypotension in Elderly Hip Surgery Starting soon
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients Recruiting
Pelvic Floor Therapies for Lifelong Premature Ejaculation Recruiting
Carotid Artery Corrected Flow Time and Inferior Vena Cava Collapsibility Index for Prediction of Hypotension After Induction of General Anesthesia in Geriatric Patients Undergoing Elective Surgery Recruiting
Laparoscopic Management of Gastroesophageal Reflux Disease in Children Recruiting

Other trials for the same condition

Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04415983 on ClinicalTrials.gov ↗ ← All trials in Egypt